Drug Discovery
Architectural Constraints and Failure Modes in AI-Driven Drug Discovery Programs
Executive Summary (TL;DR) AI-driven drug discovery failures are rarely algorithmic first. Data validity, measurement bias, and biological misalignment break earlier. Binding affinity predictions do not equate to therapeutic effect. Misinterpreting this distinction propagates costly false positives. Model interpretability constraints directly affect regulatory defensibility, reproducibility, and cross-team adoption. Infrastructure complexity emerges from data heterogeneity, not scale […]
Beyond Storage: Building a Data Fabric for AI-Driven Drug Discovery
The “Silo” Problem Data fragmentation is the number one blocker for AI adoption in Pharma. Even industry giants like Novartis have publicly noted the extreme difficulty of cleaning and linking heterogeneous data across a global organization. Valuable data sits trapped in different formats (structured SQL vs. unstructured pathology images), different legacy applications (old ELNs vs. […]
Why You Don’t Need a “Big Pharma” Budget for Quantum Drug Discovery
The Cost Barrier is Gone For decades, high-fidelity molecular modeling was a luxury reserved for the “Big Pharma” elite. Developing a new drug costs nearly $2 billion, and a significant portion of that budget goes into massive High-Performance Computing (HPC) clusters required to run complex simulations. Small biotechs and startups were forced to rely on […]
AI Data Management for Drug Discovery: Accelerating R&D with Solix EAI Pharma
What is AI Data Management in Life Sciences? We are living in the “Decade of Data.” The biomedical domain has seen an explosion of information, driven by the plummeting cost of Next Generation Sequencing (NGS), the digitization of health records, and the rise of wearable sensors. However, for most Pharma organizations, this data is a […]
Why GenAI Fails in Drug Discovery and How Semantic Data Fixes It
Introduction: The Promise vs. The Reality of Pharma AI The pharmaceutical industry is currently navigating a paradoxical “drug drought.” Over the last decade, R&D investment has skyrocketed, yet the return on investment (ROI) for the top pharmaceutical companies has plummeted dropping from roughly 10% in 2010 to under 2% recently. The industry is desperate for […]
Open-Source Structure-to-Affinity: Building Predictive Drug Discovery on OpenFold3
Key Takeaways Structure-to-affinity modeling is the missing bridge between protein structure prediction and real-world drug discovery outcomes. OpenFold3 enables reproducible, transparent protein structure generation without reliance on closed vendor APIs. Open-source affinity pipelines unlock explainability, auditability, and scientific control that black-box AI platforms cannot provide. AI-ready data platforms are required to operationalize these models at […]